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Optimizing therapeutic regimens for breast cancer  
patients has an important role to play in improving  
outcomes and optimal use of resources.  
Oncotype DX® testing has been shown to provide  
clinically valuable information in addition to 
traditional measurements (such as tumor size, tumor 
grade and lymph node status) to support 
chemotherapy treatment decision making in women 
with breast cancer. 
Reallocation of adjuvant chemotherapy based on  
Oncotype DX test results was associated with  
improvements in long-term survival and QALYs.  
The ICERs indicated that Oncotype DX would be cost  
saving or highly cost-effective, depending on the  
dataset used.  
At a willingness to pay threshold of €20,000/QALY  
(lowest cost-effectiveness threshold applied in the 
Netherlands),  the probabilistic sensitivity analysis  
showed a 100%  probability that Oncotype DX testing  
would be cost-effective versus current clinical practice 
in the Netherlands. 
Oncotype DX represents an effective and affordable  
approach to favorably affect the lives of women with  
early-stage breast cancer in the Netherlands. 
The aim of this study was to evaluate the expected  
incremental cost-effectiveness of Oncotype DX testing 
to support adjuvant therapy decision making vs. current  
clinical practice in the treatment of patients with ER+,  
early-stage breast cancer in the Netherlands.  
Oncotype DX was projected to increase mean expected  
life years (LY) by 0.07 to 0.23 years and mean expected  
QALYs by  0.20 to 0.36. Clinical benefits were driven by  
optimized allocation of adjuvant chemotherapy in the  
Oncotype DX group. Depending on which dataset was  
used, direct medical costs were estimated to be lower  
or slightly higher with Oncotype DX testing.  
This led to a range of incremental cost-effectiveness  
ratios (ICERs) from cost-saving to €626 / LY   
and €717 / QALY gained.  
Cost-effectiveness of Oncotype DX testing was  
sensitive to net changes in chemotherapy for  
low risk patients.  
A Markov model was developed to project distant  
recurrences, survival, quality-adjusted life years (QALYs)   
and direct medical costs for patients with ER+,  
node-negative or micrometastatic (pN1mic) early-stage  
breast cancer, over a time horizon of 30 years from a  
Dutch health systems perspective.   
The model compared Oncotype DX testing to inform 
treatment recommendations to conventional diagnostic  
procedures including Adjuvant! Online.  
The model was run with Dutch specific life tables for 
mortality and three respective datasets for net change 
in treatment recommendations following Oncotype DX 
testing:  
• A published meta-analysis (Hornberger et al. 2011)  
on treatment recommendations with and without  
Oncotype DX served as the base case for the model;  
• Oncotype DX study in Germany (Eiermann et al. 
2012)  
• Oncotype DX study in Wales (Holt et al. 2011).  
Costs (in 2012 euros) were derived from published  
Dutch sources.  
 
 
 
 
 
 
 
 
Following Dutch pharmacoeconomic  
guidelines, future costs were discounted at 4% and  
clinical benefits at 1.5% annually. A probabilistic  
sensitivity analysis was performed.  
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€ 12.360 
DBC- 
Distant recurrence € 1,721,00 Thomas, 2009 
(converted to €) 
Oncotype DX® € 3.180,00 Genomic Health 
